The first triple agonist — activating GLP-1, GIP, and glucagon receptors simultaneously. Clinical trials show up to 24% weight loss. Available now through physician evaluation.
· Physician evaluation required· Compounded by licensed 503A pharmacy· All 50 US states· Results within 24 hours
24%
average weight loss in Phase 2 clinical trials at 48 weeks
3x
receptor pathways activated vs single GLP-1 agonists
Phase 3
clinical development stage — most advanced pipeline
Why triple activation changes everything
Three receptors. One mechanism. Unprecedented results.
Semaglutide
GLP-1
GIP
Glucagon
~15% average
Tirzepatide
GLP-1
GIP
Glucagon
~22% average
Most Advanced
Retatrutide
GLP-1
GIP
Glucagon
Up to 24% in trials
01
Appetite regulation
GLP-1 activation slows gastric emptying, reduces appetite, and supports insulin secretion. The mechanism that Ozempic built its entire clinical record on.
02
Fat cell metabolism
GIP receptor activation improves fat metabolism directly at the adipocyte level — enhancing the fat-burning effect of GLP-1 beyond what either achieves alone.
03
Energy expenditure
The glucagon pathway increases basal metabolic rate — causing the body to burn more energy at rest. This is the mechanism that separates Retatrutide from everything before it.
The evidence
What the clinical trials show.
Retatrutide is an investigational compound currently in Phase 3 clinical development. Clinical trial data below reflects published Phase 2 results. Compounded retatrutide is not FDA-approved. Individual results will vary.
24.2%
Average weight loss
Mean weight reduction at 48 weeks in Phase 2 clinical trial participants at the highest dose studied.
NEJM 2023 Phase 2 trial data
17.5%
At moderate dose
Significant weight reduction observed even at intermediate doses, demonstrating a dose-response relationship across all study arms.
NEJM 2023 Phase 2 trial data
58%
Achieved >20% weight loss
More than half of participants at the highest dose achieved greater than 20% total body weight loss — a threshold rarely seen with any prior pharmacological intervention.
NEJM 2023 Phase 2 trial data
Metric
Semaglutide
Tirzepatide
Retatrutide
Average weight loss
15%
22%
Up to 24%
Receptors targeted
1
2
3
Metabolic rate effect
Minimal
Moderate
Significant
Phase of development
Approved
Approved
Phase 3
Patient criteria
Is Retatrutide right for you?
Eligibility is determined exclusively by a licensed physician following evaluation of your health history. The criteria below are general guidelines — not guarantees.
You may qualify:
✓BMI of 30 or greater
✓BMI of 27+ with a weight-related health condition
✓Previous GLP-1 therapy with suboptimal results or plateau
✓No history of medullary thyroid carcinoma or MEN2 syndrome
✓No current pregnancy or breastfeeding
✓No severe gastrointestinal disease
✓Willing to commit to a supervised weight management protocol
✓Seeking the most advanced GLP-1 therapy currently available
Important
Retatrutide is an investigational compound. Physician evaluation is mandatory. A prescription is not guaranteed. Your physician will determine clinical appropriateness based on your complete health history and individual risk factors.
From evaluation to treatment.
1
Complete the intake form
Fill out the health questionnaire below — approximately 8 minutes. Your physician reviews every submission personally.
2
Physician evaluation within 24 hours
A licensed physician reviews your health history and determines whether Retatrutide is clinically appropriate. You receive a clear response within 24 hours.
3
Informed consent and prescription
If approved you sign an informed consent document. Your prescription is sent to VialsRX, our licensed 503A compounding pharmacy.
4
Treatment ships within 48 hours
VialsRX prepares your compounded Retatrutide and ships directly to your address. Ongoing physician monitoring is included.
Request evaluation
Start your physician evaluation.
Complete this form to be evaluated for Retatrutide therapy. A licensed physician will review your submission within 24 hours. No commitment required.
All information is encrypted and protected under HIPAA. We will never share your health information with third parties. Physician evaluation required. A prescription is not guaranteed. Compounded Retatrutide is not an FDA-approved drug.
Questions about Retatrutide.
Retatrutide (LY3437943) is an investigational triple receptor agonist developed by Eli Lilly. It activates three hormone receptors simultaneously — GLP-1, GIP, and glucagon — producing weight loss effects that exceed those of semaglutide or tirzepatide in clinical trials. It is currently in Phase 3 clinical development.
The most advanced weight management therapy available. Physician evaluation required.
Retatrutide represents the next generation of GLP-1 science. Start with your evaluation today.
Physician supervised · All 50 states · Licensed 503A pharmacy · 24hr review
Retatrutide is an investigational compound in Phase 3 clinical development. It has not been approved by the FDA. Compounded Retatrutide prepared by VialsRX is not an FDA-approved drug and has not been evaluated by the FDA for safety, efficacy, or quality. Clinical services provided by Arora Health & Aesthetics, LLC. A prescription is not guaranteed. This page is for informational purposes only and does not constitute medical advice. Consult your physician before starting any new treatment.
Medically reviewed by Dr. Ana Lisa Carr, MD, MBA Board-Certified Family Medicine Physician · Lead Provider / Medical Reviewer NPI 1689841744 · Last reviewed: May 10, 2026
Hormone therapy addresses the hormonal causes of midlife weight gain. GLP-1s like semaglutide target appetite and metabolism. Here is how they differ — and when to use one, the other, or both.